针对顽固性2型糖尿病试验(CAPTAIN-T2D) (CAPTAIN-T2D)
Clofutriben 与安慰剂针对难治性2型糖尿病的第二阶段临床试验(CAPTAIN-T2D)
CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).
研究概览
详细说明
CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.
The trial consists of two parts.
Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.
During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Arizona
-
Chandler、Arizona、美国、85225
- 招聘中
- Arizona Clinical Trials - Pecos
-
接触:
- Kamila Manager
- 电话号码:480-470-4000
- 邮箱:kojeda@azclinicaltrials.com
-
Tucson、Arizona、美国、85711
- 招聘中
- Arizona Clinical Trials - Broadway
-
接触:
- Leanne Manager
- 电话号码:480-470-4000
- 邮箱:lbuchenholz@azclinicaltrials.com
-
-
California
-
Fountain Valley、California、美国、92708
- 招聘中
- Ark Clinical Research - Fountain Valley
-
接触:
- Lizeth Manager
- 电话号码:323-588-1990
- 邮箱:lsuncin@velocityclinical.com
-
Huntington Park、California、美国、90255
- 招聘中
- Velocity Clinical Research, Huntington Park
-
接触:
- Tim Manager
- 电话号码:5135799911
- 邮箱:tpeterson@velocityclinical.com
-
La Mesa、California、美国、91942
- 招聘中
- Velocity Clinical Research - Gardena
-
接触:
- Tim Manager
- 电话号码:513-673-4057
- 邮箱:tpeterson@velocityclinical.com
-
Long Beach、California、美国、90815
- 招聘中
- Ark Clinical Research - Long Beach
-
接触:
- Mike Manager
- 电话号码:562-997-1000
- 邮箱:mdelgado@arkclinicalresearch.com
-
Los Angeles、California、美国、90057
- 招聘中
- Velocity Clinical Research, Los Angeles
-
接触:
- Tim Manager
- 电话号码:5135799911
- 邮箱:tpeterson@velocityclinical.com
-
Los Angeles、California、美国、90015
- 招聘中
- Los Angeles Institute for Metabolic Research
-
接触:
- Lourdes Manager
- 电话号码:(213) 373-8380
- 邮箱:lgaribay@metabolic.la
-
Northridge、California、美国、98433
- 招聘中
- Amicis Research Center- Nordhoff
-
接触:
- Veronica Clinical Research Manager
- 电话号码:(818) 929-7774
- 邮箱:veronica.macias@amicisresearch.com
-
San Diego、California、美国、92120
- 招聘中
- Alliance Clinical San Diego
-
接触:
- Sandra Manager
- 电话号码:(858) 299-0009
- 邮箱:SMisic@allianceclinicalnetwork.com
-
-
Florida
-
Edgewater、Florida、美国、32132
- 招聘中
- Velocity Clinical Research, New Smyrna Beach
-
接触:
- Tim Manager
- 电话号码:513-673-4057
- 邮箱:tpeterson@velocityclinical.com
-
Fort Lauderdale、Florida、美国、33312
- 招聘中
- The Center for Diabetes and Endocrine Care
-
接触:
- Marie Study Coordinator
- 电话号码:ext 236 954-963-7191
- 邮箱:mmartin@diabetes-endocare.com
-
Miami、Florida、美国、33173
- 招聘中
- Admed Research LLC
-
接触:
- Indiana Manager
- 电话号码:786-687-2882
- 邮箱:igonzalez@admedresearch.com
-
New Port Richey、Florida、美国、34652
- 招聘中
- Suncoast Clinical Research, Inc
-
接触:
- Cathy Manager
- 电话号码:727-849-4131
- 邮箱:cbarnes@suncoastclinicalresearch.com
-
Port Charlotte、Florida、美国、33952
- 招聘中
- Innovative Research Institute
-
接触:
- Lauren Manager
- 电话号码:(+1) 2832276233
- 邮箱:l.ellis@medpace.com
-
Port Orange、Florida、美国、32127
- 招聘中
- Progressive Medical Research
-
接触:
- Nora Clinical Research Manager
- 电话号码:3457 386-304-7070
- 邮箱:norab@progressivemedicalresearch.com
-
Winter Park、Florida、美国、32789
- 招聘中
- Conquest Research
-
接触:
- Malisa Manager
- 电话号码:407-916-0060
- 邮箱:malisa.agard@conquestresearch.com
-
-
Georgia
-
Atlanta、Georgia、美国、30303
- 招聘中
- Emory University School of Medicine
-
接触:
- Rohit Manager
- 电话号码:404-778-1695
- 邮箱:rohit.parab@emory.edu
-
Columbus、Georgia、美国、31904
- 招聘中
- IACT Health-Brookstone Centre Pkwy
-
接触:
- kristina Manager
- 电话号码:706.321.0495
- 邮箱:kristina.erb@centricityresearch.com
-
-
Idaho
-
Boise、Idaho、美国、83709
- 招聘中
- Paradigm Clinical Research - Boise, ID
-
接触:
- Janaie Manager
- 电话号码:208-801-7440
- 邮箱:jbounsana@paradigm-research.com
-
-
Illinois
-
Chicago、Illinois、美国、60607
- 招聘中
- Chicago Clinical Research Institute
-
接触:
- Manognya Clinical Research Manager
- 电话号码:303 3127913241
- 邮箱:manognya@ccrii.us
-
-
Iowa
-
West Des Moines、Iowa、美国、50226
- 招聘中
- Iowa Diabetes and Endocrinology Research Center
-
接触:
- Crystal Manager
- 电话号码:515-207-7486
- 邮箱:choffman@iderc.com
-
-
Kansas
-
Wichita、Kansas、美国、67226
- 招聘中
- Alliance for Multispecialty Research - Wichita East
-
接触:
- Terry Manager
- 电话号码:316-689-6635
- 邮箱:terry.klein@amr-clinical.com
-
-
Kentucky
-
Edgewood、Kentucky、美国、41017
- 招聘中
- St. Elizabeth Healthcare
-
接触:
- Amber Manager
- 电话号码:859-655-1567
- 邮箱:amber.avery@stelizabeth.com
-
-
Louisiana
-
Lafayette、Louisiana、美国、70508
- 招聘中
- Velocity Clinical Research, Lafayette
-
接触:
- Tim Manager
- 电话号码:513-673-4057
- 邮箱:tpeterson@velocityclinical.com
-
Metairie、Louisiana、美国、70006
- 招聘中
- NOLA Care Clinical Research
-
接触:
- Rosina Manager
- 电话号码:504-427-6324
- 邮箱:rosinaducote@gmail.com
-
New Orleans、Louisiana、美国、70112
- 招聘中
- Tulane University School of Medicine
-
接触:
- Neha Manager
- 电话号码:5049889803
- 邮箱:nupadhyay@tulane.edu
-
-
Maryland
-
Rockville、Maryland、美国、20854
- 招聘中
- Velocity Clinical Research, Rockville
-
接触:
- Tim Manager
- 电话号码:513-673-4057
- 邮箱:tpeterson@velocityclinical.com
-
-
Massachusetts
-
Springfield、Massachusetts、美国、011030
- 招聘中
- Elixia SISU BHR - Springfield
-
接触:
- Darlene Manager
- 电话号码:5617970336
- 邮箱:darlene.djaba@empathxresearch.com
-
-
Michigan
-
Troy、Michigan、美国、48085
- 招聘中
- Oakland Medical Research Center
-
接触:
- Juliejo (Julie) Clinical Research Manager
- 电话号码:248-687-7412
- 邮箱:juliejolafave@msn.com
-
-
Nebraska
-
Lincoln、Nebraska、美国、68510
- 招聘中
- Velocity Clinical Research, Lincoln
-
接触:
- Tim Manager
- 电话号码:513-673-4057
- 邮箱:tpeterson@velocityclinical.com
-
Omaha、Nebraska、美国、68134
- 招聘中
- Velocity Clinical Research, Omaha
-
接触:
- Tim Manager
- 电话号码:513-673-4057
- 邮箱:tpeterson@velocityclinical.com
-
-
Nevada
-
Las Vegas、Nevada、美国、89148
- 招聘中
- Palm Research Center, Inc.
-
接触:
- Raffaela Manager
- 电话号码:702-736-5161
- 邮箱:raffaela@palmresearchcenter.com
-
Las Vegas、Nevada、美国、89108
- 招聘中
- Alliance Clinical - Las Vegas
-
接触:
- Stephanie Manager
- 电话号码:(702) 680-1500
- 邮箱:sruvalcaba@allianceclinicalnetwork.com
-
-
New York
-
Albany、New York、美国、12203
- 招聘中
- Albany Medical College
-
接触:
- Mohammed Manager
- 电话号码:518-264-4462
- 邮箱:ismailmoh@amc.edu
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27514
- 招聘中
- University of North Carolina at Chapel Hill
-
接触:
- Jessica Manager
- 电话号码:984-974-3004
- 邮箱:jessica_caffey@med.unc.edu
-
Greenville、North Carolina、美国、27834
- 招聘中
- Physicians East
-
接触:
- Kristen Manager
- 电话号码:252-413-6392
- 邮箱:ktaylor@physicianseast.com
-
Morehead City、North Carolina、美国、28557
- 招聘中
- Lucas Research Inc
-
接触:
- Christina Manager
- 电话号码:252-222-5700
- 邮箱:christina.tornes@centricityresearch.com
-
Wilmington、North Carolina、美国、28401
- 招聘中
- PMG Research of Wilmington, LLC
-
接触:
- Kevin Manager
- 电话号码:910.815.6108
- 邮箱:cannon1099@me.com
-
-
Ohio
-
Cincinnati、Ohio、美国、45219
- 招聘中
- Velocity Clinical Research, Cincinnati, Mt. Auburn
-
接触:
- Tim Manager
- 电话号码:513-673-4057
- 邮箱:tpeterson@velocityclinical.com
-
Cincinnati、Ohio、美国、45242
- 招聘中
- Velocity Clinical Research - Cincinnati, Blue Ash
-
接触:
- Tim Manager
- 电话号码:513-673-4057
- 邮箱:tpeterson@velocityclinical.com
-
Columbus、Ohio、美国、43201
- 招聘中
- Endocrinology Associates, Inc
-
接触:
- Edward Clinical Research Manager
- 电话号码:614-453-9999
- 邮箱:ek@endocrinology-associates.com
-
Columbus、Ohio、美国、43215
- 招聘中
- Remington Davis, Inc
-
接触:
- Tsunami Clinical Research Manager
- 电话号码:614-487-2560
- 邮箱:Tbrisco@remdavis.com
-
-
Oregon
-
Eugene、Oregon、美国、97404
- 招聘中
- Willamette Valley Clinical Studies
-
接触:
- Patricia Manager
- 电话号码:541-461-0132
- 邮箱:drpatb@aol.com
-
-
Pennsylvania
-
West Chester、Pennsylvania、美国、19380
- 招聘中
- Suburban Research Associates
-
接触:
- Tom Manager
- 电话号码:610-891-9024
- 邮箱:tfrancis@suburbanresearch.com
-
-
South Carolina
-
Anderson、South Carolina、美国、29621
- 招聘中
- Velocity Clinical Research, Anderson
-
接触:
- Tim Manager
- 电话号码:(864) 965-0190
- 邮箱:tpeterson@velocityclinical.com
-
Mt. Pleasant、South Carolina、美国、29464
- 招聘中
- Accellacare Charleston
-
接触:
- Dhruva Manager
- 电话号码:(843) 849-1880
- 邮箱:dhruva.patel@accellacare.com
-
-
Texas
-
Austin、Texas、美国、78759
- 招聘中
- Velocity Clinical Research, Austin
-
接触:
- Tim Manager
- 电话号码:513-673-4057
- 邮箱:tpeterson@velocityclinical.com
-
Dallas、Texas、美国、75230
- 招聘中
- Velocity Clinical Research - Dallas
-
接触:
- Tim Manager
- 电话号码:(972) 566-8631
- 邮箱:tpeterson@velocityclinical.com
-
Houston、Texas、美国、77040
- 招聘中
- Juno Research, LLC
-
接触:
- Lian manager
- 电话号码:713-779-5494
- 邮箱:lian_ramos@junoresearch.us
-
Lampasas、Texas、美国、76550
- 招聘中
- Radiance Clinical Research
-
接触:
- Lauren Clinical Research Manager
- 电话号码:512-556-4130
- 邮箱:lgarner@radianceclinical.com
-
Lewisville、Texas、美国、75057
- 招聘中
- Alliance Clinical - Lewisville (Epic Clinical Research)
-
接触:
- Jessica Manager
- 电话号码:(469) 361-8007
- 邮箱:jpowell@allianceclinicalnetwork.com
-
Mission、Texas、美国、78572
- 招聘中
- Texas Valley Clinical Research - Mission, TX
-
接触:
- Omar Manager
- 电话号码:9568887400
- 邮箱:gonzalez.md@tvcrmission.com
-
Round Rock、Texas、美国、78681
- 招聘中
- Texas Diabetes & Endocrinology, P.A. - Round Rock
-
接触:
- Olivia Clinical Research Manager
- 电话号码:512-334-3505
- 邮箱:knutty@tderesearch.com
-
San Antonio、Texas、美国、78229
- 招聘中
- Diabetes & Glandular Disease Clinic, P.A.
-
接触:
- Myriam Manager
- 电话号码:1532 210-614-8612
- 邮箱:myriam.turner@dgdclinic.com
-
San Antonio、Texas、美国、78251
- 招聘中
- Texas Valley Clinical Research - San Antonio TX
-
接触:
- Diana Manager
- 电话号码:2105431990
- 邮箱:diana@tvcrtrials.com
-
Seabrook、Texas、美国、77586
- 招聘中
- Elevate Clinical Research
-
接触:
- Olga Clinical Research Manager
- 电话号码:832-271-1598
- 邮箱:olga.konshina@elevateclinical.com
-
Weslaco、Texas、美国、78596
- 招聘中
- Texas Valley Clinical Research, LLC
-
接触:
- Czarina Manager
- 电话号码:956-431-8090
- 邮箱:czarina@tvcrtrials.com
-
-
Utah
-
West Jordan、Utah、美国、84088
- 招聘中
- Velocity Clinical Research, Salt Lake City
-
接触:
- Tim Clinical Research Manager
- 电话号码:5135799911
- 邮箱:tpeterson@velocityclinical.com
-
-
Virginia
-
Suffolk、Virginia、美国、23435
- 招聘中
- Velocity Clinical Research, Suffolk
-
接触:
- Tim Manager
- 电话号码:(757) 996-4200
- 邮箱:tpeterson@velocityclinical.com
-
Vienna、Virginia、美国、22182
- 招聘中
- Conquest Research
-
接触:
- Henry Manager
- 电话号码:703-372-3268
- 邮箱:Henry.Tran@conquestresearch.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
From Screening 1
-
Age at least 18 years.
-
HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).
-
Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).
-
Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.
-
Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.
-
At least one of the following
- ≥3 stable and adequate ADMs;
- diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
- hypertension requiring ≥2 adequately dosed AHMs;
- adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
- adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
- evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
- or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.
-
At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.
At Screening 2
- HbA1c ≥7.5% at Screening 2. At Day 1
- No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.
Exclusion Criteria:
-
New-onset diabetes (onset <1 year in the past).
-
Unwillingness to maintain with current glucose-lowering regimen during the trial.
-
Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.
-
Unwillingness to comply with CGM or other trial procedures.
-
Investigator considers the patient will otherwise be unwilling or unable to complete the trial.
-
Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.
-
Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).
-
Any of the following in medical history:
- Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
- A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
- Hypersensitivity or severe reaction to dexamethasone;
- Pheochromocytoma, or suspicion thereof;
- Anorexia, or other eating disorder;
- Glucocorticoid resistance;
- Multiple sclerosis;
- Significant hepatic impairment (e.g., Child-Pugh Class B or C);
- Idiopathic thrombocytopenic purpura;
- Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
- Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
- Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
- Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
- Any of the following in medication history:
- Any of the excluded medications listed in Section 6.9;
- Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
- Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
- Pregnancy (including a positive urine test) or current breast feeding.
From Screening 2
• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:
- wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
- a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
- supraclavicular/dorsocervical fat accumulation;
- irounding of the face (especially compared with prior photos);
- skin changes (violaceous striae, skin thinning, or excessive bruising);
- proximal muscle weakness on exam; or
- history of deep vein thrombosis/pulmonary embolism.
- Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
- Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
- Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
- Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
- Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
- Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
- Known hypersensitivity to clofutriben or to any of the product
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Dose 1
clofutriben .2 mg oral tablet daily |
HSD-1 inhibitor
其他名称:
|
|
实验性的:Dose 2
clofutriben 2mg oral tablet daily |
HSD-1 inhibitor
其他名称:
|
|
实验性的:Dose 3
clofutriben 6mg oral tablet daily |
HSD-1 inhibitor
其他名称:
|
|
实验性的:Dose 4
clofutriben 12 mg oral tablet daily |
HSD-1 inhibitor
其他名称:
|
|
安慰剂比较:placebo
placebo control oral tablet daily |
Placebo |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
大体时间:8-10 hours after the dexamethasone 1 mg dose.
|
To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose. |
8-10 hours after the dexamethasone 1 mg dose.
|
|
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
大体时间:24 weeks.
|
To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks. |
24 weeks.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.
大体时间:24 weeks
|
To assess glucose (mmol/L) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks. |
24 weeks
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To evaluate the safety of clofutriben in participants with T2D and EC.
大体时间:From enrollment until end of trial 9 month
|
Frequency of TEAEs (treatment-emergent adverse even) by clofutriben dose |
From enrollment until end of trial 9 month
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.